Sugi Predict

Sugi Predict / Compounds / SCHEMBL35457

SCHEMBL35457

SCHEMBL35457

CC(C)(C)OC(=O)N1CCC(C=O)C1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.49
▸ RECQL P46063 1/20 0.47
▸ EPHX1 P07099 1/20 0.47
▸ MAPT P10636 2/20 0.45
▸ USP2 O75604 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ GPR119 Q8TDV5 4/20 0.43
▸ NR1H2 P55055 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ PTPN2 P17706 1/20 0.43
▸ PTPN1 P18031 1/20 0.43
▸ PTPN6 P29350 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL35456 1.00 HPGD (0.49) HPGDRECQLEPHX1MAPTUSP2
SCHEMBL935410 1.00 HPGD (0.49) HPGDRECQLEPHX1MAPTUSP2
SCHEMBL192730 0.90 MEN1 (0.52) HPGDRECQLEPHX1MAPTUSP2
SCHEMBL641613 0.90 MEN1 (0.52) HPGDRECQLEPHX1MAPTUSP2
SCHEMBL1992277 0.90 MEN1 (0.52) HPGDRECQLEPHX1MAPTUSP2
SCHEMBL227336 0.90 HPGD (0.55) HPGDRECQLEPHX1MAPTUSP2
SCHEMBL16039992 0.89 HPGD (0.52) HPGDRECQLEPHX1MAPTUSP2
SCHEMBL478842 0.86 NR1H2 (0.51) HPGDRECQLEPHX1MAPTUSP2
SCHEMBL2934489 0.85 GPR119 (0.46) MAPTGPR119KDM4ETHRBPTPN2
SCHEMBL1279722 0.85 HPGD (0.48) HPGDRECQLEPHX1MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 813 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111960983-A N-methyl-3- (1-methylpyrrolidine-3-yl) propyl-1-amine and synthetic method thereof 南通大学 2020-11-20 — — CN claimed
CN-106588738-B The synthetic method of N-Boc-3- pyrrolidine formaldehyde 武汉恒和达生物医药有限公司 2019-03-05 — — CN claimed
CN-109232350-A A method of preparing N-Boc-3- pyrrolidine formaldehyde 辽宁东科药业有限公司 2019-01-18 — — CN claimed
US-20140309192-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC, 2014-10-16 — — US claimed
CN-103130800-A 1,3,6,9-substitution beta-carboline compound and preparation method thereof WUXI APPTEC CO LTD 2013-06-05 — — CN claimed
EP-2085395-A1 Arylvinylazacycloalkane compounds and methods of preparation and use thereof Targacept, Inc. (US) 2009-08-05 — — EP claimed
US-20090099157-A1 TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. 2009-04-16 — — US claimed
US-20080275085-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 — — US claimed
EP-4739390-A1 2-(1H-INDOL-4-YL)METHYL)2H-INDAZOLE DERIVATIVES AS FACTOR B INHIBITORS Sitala Bio Ltd (GB) 2026-05-13 — — EP disclosed
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof ALECTOS THERAPEUTICS 1NC (CA) 2026-04-28 — — US disclosed
EP-4725560-A2 ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2026-04-15 — — EP disclosed
EP-3455234-B1 SECO MACROLIDE COMPOUNDS SELVITA D O O (HR) 2026-04-01 — — EP disclosed
EP-3966199-B1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC (CA) 2026-03-18 — — EP disclosed
US-12569564-B2 Spirocyclic MDM2 modulator and uses thereof NEWAVE PHARMACEUTICAL INC. (US) 2026-03-10 — — US disclosed
WO-2004005255-A1 N-BENZYL-3-PHENYL-3-HETEROCYCLYL-PROPIONAMIDE COMPOUNDS AS TACHYKININ AND/ OR SEROTONIN REUPTAKE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-01-15 — — WO disclosed
EP-0902027-B1 Indole and indazole derivatives, process for their preparation and the pharmaceutical compositions containing them ADIR (FR) 2001-07-25 — — EP disclosed
US-6046205-A FOR TREATMENT OF VENOUS INSUFFICIENCY AND OF ASSOCIATED DISORDERS, AND ALSO IN THE TREATMENT OF MIGRAINE ADIR ET COMPAGNIE (FR) 2000-04-04 — — US disclosed
US-6020336-A Indole and indazole compounds LES LABORATOIRES SERVIER (FR) 2000-02-01 — — US disclosed
EP-0902027-A1 Indole and indazole derivatives, process for their preparation and the pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1999-03-17 — — EP disclosed
US-3976660-A Pyrrolidine derivatives E. R. SQUIBB & SONS, INC. (US) 1976-08-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275085-A1 Piperidine derivative and use thereof TACR2, TACR1, PRLHR HPGD 4250/4885RECQL 4713/4885EPHX1 3439/4885
US-12569564-B2 Spirocyclic MDM2 modulator and uses thereof MDM2, TP53, XIAP HPGD 2935/4885RECQL 446/4885EPHX1 2954/4885
US-20090099157-A1 TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S CTSS, CTSE, CTSK HPGD 1573/4885RECQL 4600/4885EPHX1 2129/4885
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof GBA1, GBA2, MAN2B1 HPGD 4101/4885RECQL 4200/4885EPHX1 1284/4885
US-20140309192-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO MRGPRX1, MRGPRX2, AGTR1 HPGD 709/4885RECQL 2414/4885EPHX1 1463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.